KRAS and lung carcinoma: Small molecules targeting HIF1A-As2 and MYC significantly inhibit tumor growth, suggesting lncRNA HIF1A-As2 presents an important biological and clinical impact in lung cancer, particularly in KRAS-driven NSCLC.